S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
NASDAQ:MBRX

Moleculin Biotech - MBRX Stock Forecast, Price & News

$1.23
0.00 (0.00%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.18
▼
$1.25
50-Day Range
$1.06
▼
$1.49
52-Week Range
$0.82
▼
$2.05
Volume
71,044 shs
Average Volume
46,021 shs
Market Capitalization
$35.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Moleculin Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
753.7% Upside
$10.50 Price Target
Short Interest
Healthy
0.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$166,132 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.10) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

443rd out of 1,028 stocks

Pharmaceutical Preparations Industry

210th out of 501 stocks

See Top Rated MarketRank™ Stocks Here
MBRX stock logo

About Moleculin Biotech (NASDAQ:MBRX) Stock

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Stock News Headlines

January 30, 2023 | americanbankingnews.com
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com
January 15, 2023 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Achilles Therapeutics (ACHL), Cidara Therapeutics (CDTX) and Moleculin Biotech (MBRX)
February 5, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
January 5, 2023 | finance.yahoo.com
Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event
December 21, 2022 | finance.yahoo.com
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
December 19, 2022 | finance.yahoo.com
Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?
December 17, 2022 | markets.businessinsider.com
Maxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX)
December 15, 2022 | finance.yahoo.com
Moleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response Rate
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 15, 2022 | finance.yahoo.com
Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)
December 7, 2022 | marketwatch.com
Moleculin Gets FDA Fast-Track Designation for WP1122 in Glioblastoma Multiforme >MBRX
December 7, 2022 | markets.businessinsider.com
Moleculin Announces FDA Fast Track Designation For WP1122
November 15, 2022 | finance.yahoo.com
Biotech firm Moleculin touts strong cash position, clinical trials in Q3 earnings call
November 10, 2022 | finance.yahoo.com
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
November 7, 2022 | thestreet.com
How to Invest in Biotechnology
November 7, 2022 | finance.yahoo.com
Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast
October 14, 2022 | finance.yahoo.com
Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
September 27, 2022 | msn.com
Moleculin Biotech's Potential Antiviral Compound Selected For NIAID-Funded Animal Studies
September 27, 2022 | finance.yahoo.com
Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral
September 23, 2022 | finance.yahoo.com
Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event
September 8, 2022 | finance.yahoo.com
Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
September 7, 2022 | finance.yahoo.com
Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022 | nasdaq.com
Moleculin Biotech Announces Receipt Of Orphan Drug Designation For WP1122 - Quick Facts
August 19, 2022 | finance.yahoo.com
Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
August 16, 2022 | seekingalpha.com
Moleculin Biotech GAAP EPS of -$0.24
August 15, 2022 | finance.yahoo.com
Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update
June 16, 2022 | finance.yahoo.com
Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
See More Headlines
Receive MBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter.

MBRX Company Calendar

Last Earnings
11/10/2022
Today
2/04/2023
Next Earnings (Estimated)
3/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBRX
CUSIP
N/A
CIK
1659617
Web
www.moleculin.com
Phone
(713) 300-5160
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+753.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.87)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,890,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.62%
Return on Assets
-36.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.41
Quick Ratio
8.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.76 per share
Price / Book
0.45

Miscellaneous

Outstanding Shares
28,628,000
Free Float
27,569,000
Market Cap
$35.21 million
Optionable
Not Optionable
Beta
2.00

Key Executives

  • Walter V. Klemp
    Chairman, President & Chief Executive Officer
  • Jonathan P. Foster
    Chief Financial Officer & Executive Vice President
  • Robert Shepard
    Chief Medical Officer-Annamycin
  • Donald H. Picker
    Chief Scientific Officer
  • Sandra Leta Silberman
    Chief Medical Officer-New Products

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions













MBRX Stock - Frequently Asked Questions

Should I buy or sell Moleculin Biotech stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MBRX shares.
View MBRX analyst ratings or view top-rated stocks.

What is Moleculin Biotech's stock price forecast for 2023?

1 analysts have issued 12 month price targets for Moleculin Biotech's shares. Their MBRX share price forecasts range from $5.00 to $16.00. On average, they anticipate the company's share price to reach $10.50 in the next year. This suggests a possible upside of 753.7% from the stock's current price.
View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts.

How have MBRX shares performed in 2023?

Moleculin Biotech's stock was trading at $1.06 at the beginning of 2023. Since then, MBRX shares have increased by 16.0% and is now trading at $1.23.
View the best growth stocks for 2023 here.

Are investors shorting Moleculin Biotech?

Moleculin Biotech saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 77,200 shares, a decrease of 34.9% from the December 31st total of 118,600 shares. Based on an average daily volume of 101,300 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.3% of the shares of the company are sold short.
View Moleculin Biotech's Short Interest.

When is Moleculin Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our MBRX earnings forecast.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its earnings results on Thursday, November, 10th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.03. During the same period last year, the company earned ($0.15) earnings per share.

When did Moleculin Biotech's stock split?

Moleculin Biotech shares reverse split on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How do I buy shares of Moleculin Biotech?

Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $1.23.

How much money does Moleculin Biotech make?

Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $35.21 million. The company earns $-15,890,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com.

This page (NASDAQ:MBRX) was last updated on 2/5/2023 by MarketBeat.com Staff